Alpha-Antitrypsin Deficiency - Epidemiology Forecast to 2025

  • ID: 4330786
  • Report
  • 50 pages
  • DelveInsight
1 of 3
This report provides an overview of the epidemiology trends of Alpha Antitrypsin Deficiency in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data. The report also discusses the prevailing risk factors and disease burden with special emphasis on unmet medical needs. The report contains targeted patient populations and forecast methodology.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house forecast model analysis by a team of industry experts.

Key Coverage and Benefits
  • The report includes the prevalent population and how will it change over the next eight years.
  • Coverage of key Alpha Antitrypsin Deficiency sub-populations and its prevalent or incident cases.
  • Prevalent or incident cases segmented by age and sex.
  • The key differences in epidemiology patterns across the seven market segments.
Reasons to Buy
  • Developing business strategies by understanding the trends shaping and driving the global Alpha Antitrypsin Deficiency market.
  • Identifying prevalent patient populations as well as risk factors in the global Alpha Antitrypsin Deficiency market will help to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the best opportunities for Alpha Antitrypsin Deficiency therapeutics in each of the markets covered.
Note: Product cover images may vary from those shown
2 of 3
1. Report Introduction

2. Alpha Antitrypsin Deficiency Epidemiology Overview at a Glance
2.1. Prevalent Population of Alpha Antitrypsin Deficiency in 20
2.2. Prevalent Population of Alpha Antitrypsin Deficiency in 20

3. Disease Background and Overview: Alpha Antitrypsin Deficiency
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Genetic Inheritance of Alpha Antitrypsin Deficiency
3.6. Pathophysiology
3.7. Complications
3.8. Diagnosis
3.9. Treatment
3.10. Diagnostic Delay

4. Epidemiology and Patient Population
4.1. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM
4.2. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM – By Region
4.3. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM – Distribution (2016)
4.4. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM – Distribution (2027)
4.5. Epidemiology of Alpha-1-Antitrypsin Deficiency- By Country
4.5.1. United States
4.5.1.1. Assumptions and Rationale
4.5.1.2. Population at risk of Alpha Antitrypsin Deficiency in United States
4.5.1.3. Prevalent Population of Alpha Antitrypsin Deficiency
4.5.2. EU
4.5.2.1. Assumptions and Rationale
4.5.2.2. Germany
4.5.2.2.1. Population at risk of Alpha Antitrypsin Deficiency in Germany
4.5.2.2.2. Prevalent Population of Alpha Antitrypsin Deficiency in Germany
4.5.2.3. France
4.5.2.3.1. Population at risk of Alpha Antitrypsin Deficiency in France
4.5.2.3.2. Prevalent Population of Alpha Antitrypsin Deficiency in France
4.5.2.4. Italy
4.5.2.4.1. Population at risk of Alpha Antitrypsin Deficiency in Italy
4.5.2.4.2. Prevalent Population of Alpha Antitrypsin Deficiency in Italy
4.5.2.5. Spain
4.5.2.5.1. Population at risk of Alpha Antitrypsin Deficiency in Spain
4.5.2.5.2. Prevalent Population of Alpha Antitrypsin Deficiency in Spain
4.5.2.6. United Kingdom
4.5.2.6.1. Population at risk of Alpha Antitrypsin Deficiency in UK
4.5.2.6.2. Prevalent Population of Alpha Antitrypsin Deficiency in UK
4.5.3. Japan
4.5.3.1. Diagnosed Population of Alpha Antitrypsin Deficiency in Japan

5. Appendix

6. Report Methodology
6.1. Sources Used

7. Consulting Services

8. Disclaimer

9. About the Publisher

List of Tables:
Table 1: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2016-2027)
Table 2: Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM (2016-2027)
Table 3: Population at risk of Alpha Antitrypsin Deficiency in United States (2016-2027)
Table 4: Prevalent Population of Alpha Antitrypsin Deficiency in United States (2016-2027)
Table 5: Population at risk of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Table 6: Prevalent Population of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Table 7: Population at risk of Alpha Antitrypsin Deficiency in France (2016-2027)
Table 8: Prevalent Population of Alpha Antitrypsin Deficiency in France (2016-2027)
Table 9: Population at risk of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Table 10: Prevalent Population of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Table 11: Population at risk of Alpha Antitrypsin Deficiency in Spain (2016-2027)
Table 12: Prevalent Population of Alpha Antitrypsin Deficiency in Spain (2016-2027)
Table 13: Population at risk of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Table 14: Prevalent Population of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Table 15: Diagnosed Population of Alpha Antitrypsin Deficiency in Japan (2016-2027)

List of Figures:
Figure 1: Pathogenesis of Alpha Antitrypsin Deficiency
Figure 2: Diagnostic Algorithm of Alpha Antitrypsin Deficiency
Figure 3: General Treatment of Alpha Antitrypsin Deficiency
Figure 4: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2016-2027)
Figure 5: Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM (2016-2027)
Figure 6: Population at risk of Alpha Antitrypsin Deficiency in United States (2016-2027)
Figure 7: Prevalent Population of Alpha Antitrypsin Deficiency in United States (2016-2027)
Figure 8: Population at risk of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Figure 9: Prevalent Population of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Figure 10: Population at risk of Alpha Antitrypsin Deficiency in France (2016-2027)
Figure 11: Prevalent Population of Alpha Antitrypsin Deficiency in France (2016-2027)
Figure 12: Population at risk of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Figure 13: Prevalent Population of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Figure 14: Population at risk of Alpha Antitrypsin Deficiency in Spain ( (2016-2027)
Figure 15: Prevalent Population of Alpha Antitrypsin Deficiency in Spain (2016-2027)
Figure 16: Population at risk of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Figure 17: Prevalent Population of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Figure 18: Diagnosed Population of Alpha Antitrypsin Deficiency in Japan (2016-2027)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll